Zobrazeno 1 - 10
of 749
pro vyhledávání: '"Yuankai SHI"'
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-18 (2024)
Abstract Spread through air spaces (STAS) is a recognized aggressive pattern in lung cancer, serving as a crucial risk factor for postoperative recurrence. However, its phenotype and related spatial structure have remained elusive. To address these l
Externí odkaz:
https://doaj.org/article/2901c635151c4c1f86c0a29f6b18b050
Autor:
Changgong Zhang, Jianhua Chen, Huijuan Wu, Jun Wang, Liying Gao, Jun Zhao, Yan Sun, Zhongyao Jia, Xinlin Mu, Chunmei Bai, Rui Wang, Kailiang Wu, Qiang Liu, Yuankai Shi
Publikováno v:
Cancer Pathogenesis and Therapy, Vol 2, Iss 4, Pp 268-275 (2024)
Background: Currently, the need for new therapeutic strategies involving programmed cell death protein-1 (PD-1) monoclonal antibodies in the second-line setting of small cell lung cancer (SCLC) is urgent. This study aimed to evaluate the efficacy and
Externí odkaz:
https://doaj.org/article/8c004d4703c04f11bcf54cc95c9a6d8d
Autor:
Haohua Zhu, Yufeng Cao, Jingyu Lu, Lei Guo, Rongrong Luo, Huiyang Shi, Yu Feng, Yutao Liu, Puyuan Xing, Hongyu Wang, Yuankai Shi, Jie Ma, Xingsheng Hu, Peifang Wei
Publikováno v:
Chinese Medical Journal, Vol 137, Iss 20, Pp 2501-2503 (2024)
Externí odkaz:
https://doaj.org/article/9984dadf02be43c7ae2d83959914a1db
Autor:
Ruyun Gao, Ning Lou, Lin Li, Tongji Xie, Puyuan Xing, Le Tang, Jiarui Yao, Xiaohong Han, Yuankai Shi
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Introduction Identifying new biomarkers for predicting immune checkpoint inhibitors (ICIs) response in non-small cell lung cancer (NSCLC) is crucial. We aimed to assess the variant allele frequency (VAF)-related profile as a novel biomarker
Externí odkaz:
https://doaj.org/article/01d8a74ab1f0446cac8f66bf6e86e1fd
Autor:
Yuankai Shi, Xiaohong Han, Qian Zhao, YuLong Zheng, Jianhua Chen, Xinmin Yu, Jian Fang, Yutao Liu, Dingzhi Huang, Tianshu Liu, Hong Shen, Suxia Luo, Hongsheng Yu, Yu Cao, Xi Zhang, Pei Hu
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2024)
Abstract Background Tunlametinib (HL-085) is a novel, highly selective MEK inhibitor with substantial clinical activities in patients with NRAS-mutant melanoma. This phase I study evaluated the safety and preliminary efficacy of tunlametinib plus vem
Externí odkaz:
https://doaj.org/article/0f192aa657bc4c0d996fc74a75cf28e7
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-25 (2024)
Abstract Background Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignancy characterized by varied responses to treatment and prognoses. Understanding the metabolic characteristics driving DLBCL progression is crucial for developing pers
Externí odkaz:
https://doaj.org/article/140674df43274333abe54ca203218d11
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 9, Pp n/a-n/a (2024)
Abstract Intra‐tumour immune infiltration is a crucial determinant affecting immunotherapy response in non‐small cell lung cancer (NSCLC). However, its phenotype and related spatial structure have remained elusive. To overcome these restrictions,
Externí odkaz:
https://doaj.org/article/7f45e31e59ea47cea124100767cd8b7a
Autor:
Puyuan Xing, Shanbing Wang, Minghong Bi, Yong Liu, Jia Zeng, Xicheng Wang, Ke Xiao, Weidong Li, Jun Guo, Pu Wang, Yueyin Pan, Biyong Ren, Emei Gao, Lei Zhang, Yingchun Wang, Tianyi Gan, Guang Cheng, Yuankai Shi
Publikováno v:
EClinicalMedicine, Vol 75, Iss , Pp 102791- (2024)
Summary: Background: This was a multicenter, single-arm dose-ranging phase 2 study aimed to assess the efficacy and safety of LY01610, a liposomal irinotecan, at various doses for patients with relapsed small cell lung cancer (SCLC). Methods: This st
Externí odkaz:
https://doaj.org/article/36ddc04b9f51424597c83e4755d54a25
Publikováno v:
Cancer Pathogenesis and Therapy, Vol 2, Iss 2, Pp 103-111 (2024)
Background: Chemotherapy remains the standard-of-care for many patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC), but acquired resistance presents challenges. The aim of this open-label, multicenter phase 2 clinical tria
Externí odkaz:
https://doaj.org/article/feec319524834ec39d25c999ea53f1d8
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-16 (2024)
Abstract In hepatocellular carcinoma (HCC), classical cancer stem cells (CSC) markers were shared by normal stem cells, targeting which may hinder hepatic regeneration and cause liver failure. Additionally, the spatial structure of CSC still remained
Externí odkaz:
https://doaj.org/article/75f5b29ff4ac4d5993f48a60725f5cd9